Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes (Nasdaq: ALKS) announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alkermes (Nasdaq: ALKS) announced its participation in two upcoming investor conferences. Management will present at the Jefferies Healthcare Conference on June 6, 2024, at 1:30 p.m. EDT and at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 10:40 a.m. EDT. The presentations will be webcast live and available under the Investors tab on Alkermes' website for 14 days. Alkermes is a biopharmaceutical company with a portfolio targeting alcohol and opioid dependence, schizophrenia, and bipolar I disorder, along with a pipeline for neurological disorders.
Positive
- Alkermes' participation in prominent investor conferences may enhance visibility and attract investor interest.
- Webcasting the presentations live provides accessibility and transparency for current and potential investors.
- The company's diverse product portfolio and pipeline indicate a strong focus on treating significant neurological and psychiatric conditions.
Negative
- The announcement lacks specific new financial data or clinical trial results, potentially reducing its immediate impact on stock performance.
- No updates on revenue or profitability, which could be a concern for investors looking for financial performance indicators.
Details
News Market Reaction – ALKS
The recorded move for ALKS in the trading session of this news was -0.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Jefferies Healthcare Conference
Date/Time: Thursday, June 6, 2024 at 1:30 p.m. EDT (6:30 p.m. BST)
Goldman Sachs 45th Annual Global Healthcare Conference
Date/Time: Tuesday, June 11, 2024 at 10:40 a.m. EDT (3:40 p.m. BST)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-two-upcoming-investor-conferences-302158279.html
SOURCE Alkermes plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.